Orciprenaline
beta2-Adrenergic Agonist — RESPIRATORY SYSTEM
Also known as: metaproterenol, metaproterenol sulfate, orciprenaline sulfate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Orciprenaline is an ofp drug in the beta2-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1973. Its mechanism of action is classified as Adrenergic beta2-Agonists. DrugCentral lists 2 molecular targets, including ADRB2 and ADRB2. Recorded indications include Acute exacerbation of asthma, Asthma, Asthma management and Bronchitis.
- Approval status: ofp (first approved 1973 by the FDA).
- Drug class: beta2-Adrenergic Agonist.
- Mechanism of action: Adrenergic beta2-Agonists.
- Molecular targets: ADRB2 and ADRB2 (2 listed in DrugCentral).
- Indications: Acute exacerbation of asthma, Asthma, Asthma management, Bronchitis and Bronchospasm Prevention and others.
- ATC code: R03AB03 (Non-selective beta-adrenoreceptor agonists).
- Molecular formula: C11H17NO3; molecular weight 211.26 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchitis
- Bronchospasm Prevention
- Pulmonary emphysema
Contraindications (8)
- Chronic heart failure
- Diabetes mellitus
- Disorder of coronary artery
- Hypertensive disorder
- Hyperthyroidism
- Myocardial ischemia
- Seizure disorder
- Tachyarrhythmia
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic beta2-Agonists |
|---|---|
| Established pharmacologic class | beta2-Adrenergic Agonist |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-2 adrenergic receptor | ADRB2 | agonist | Kd 6.30 |
| Beta-2 adrenergic receptor | ADRB2 | unknown | Kd 5.04 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1973-07-31 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R03AB03 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Non-selective beta-adrenoreceptor agonists |
R03CB03 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists |
R03CB53 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Orciprenaline is on its molecule page.
| Molecular formula | C11H17NO3 |
|---|---|
| Molecular weight | 211.26 g/mol |
| CAS number | 586-06-1 |
| InChIKey | LMOINURANNBYCM-UHFFFAOYSA-N |
| PubChem CID | 4086 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Orciprenaline used for?
DrugCentral lists the following indications for Orciprenaline: Acute exacerbation of asthma, Asthma, Asthma management, Bronchitis, Bronchospasm Prevention and Pulmonary emphysema.
How does Orciprenaline work?
Orciprenaline is classified as Adrenergic beta2-Agonists; its molecular targets in DrugCentral include ADRB2 (agonist) and ADRB2.
When was Orciprenaline first approved?
Orciprenaline was first approved by the FDA in 1973.
What drug class does Orciprenaline belong to?
Orciprenaline is in the beta2-Adrenergic Agonist class.
What is the chemical formula of Orciprenaline?
Orciprenaline has the molecular formula C11H17NO3 and a molecular weight of 211.26 g/mol.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1720 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1568057 — compound record and bioactivity
- PubChem CID 4086 — chemical identifiers
- DrugBank DB00816 — drug record
- FDA UNII 53QOG569E0 — substance identity
- DailyMed: FDA labels for Orciprenaline — current prescribing information (label search)
- UniProt P07550 (ADRB2) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.